Revelation Biosciences, Inc.
REVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $3,549 | $4,146 | $5,377 | $6,915 |
| G&A Expenses | $4,426 | $4,511 | $5,487 | $5,036 |
| SG&A Expenses | $4,426 | $4,511 | $5,487 | $5,036 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7,975 | $8,657 | $10,865 | $11,950 |
| Operating Income | -$7,975 | -$8,657 | -$10,865 | -$11,950 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$7,063 | $8,536 | $35 | -$36 |
| Pre-Tax Income | -$15,039 | -$120 | -$10,830 | -$11,987 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$15,039 | -$120 | -$10,830 | -$11,987 |
| % Margin | – | – | – | – |
| EPS | -87.68 | -8.41 | -9,643.37 | -20,400 |
| % Growth | -942.6% | 99.9% | 52.7% | – |
| EPS Diluted | -87.68 | -8.41 | -9,643.37 | -20,400 |
| Weighted Avg Shares Out | 172 | 14 | 1 | 1 |
| Weighted Avg Shares Out Dil | 172 | 14 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $42 |
| Depreciation & Amortization | $28 | $25 | $25 | $17 |
| EBITDA | -$7,947 | -$8,632 | -$10,839 | -$11,934 |
| % Margin | – | – | – | – |